Peptek

Peptek is a South Korean biotechnology company specializing in the discovery and development of peptide-based therapeutics for high-need clinical areas, including ophthalmology and oncology. Founded in 2001, the company utilizes its proprietary peptide library and mapping technologies to identify bioactive sequences that can modulate key biological pathways. Its lead candidate, PTK-001, is a peptide-derived angiogenesis inhibitor that targets vascular endothelial growth factor (VEGF) to treat neovascular eye diseases such as age-related macular degeneration. In addition to its therapeutic pipeline, Peptek provides specialized peptide synthesis services and develops functional peptide ingredients for the cosmeceutical industry. The company is headquartered in the biotech cluster of Daejeon, South Korea.